⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9387320 | 0.94 | — | — | |
| SCHEMBL176076 | 0.92 | EPHX1 (0.39) | — | |
| Hydrochloric Acid SCHEMBL4416986 | 0.90 | KDM4E (0.38) | — | |
| Hydrochloric Acid SCHEMBL4409590 | 0.90 | KDM4E (0.38) | — | |
| SCHEMBL7166980 | 0.88 | — | — | |
| SCHEMBL8926767 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL2773491 | 0.86 | — | — | |
| SCHEMBL4019377 | 0.77 | DPP4 (0.33) | — | |
| SCHEMBL7859411 | 0.77 | — | — | |
| SCHEMBL10482352 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002531400-A | — | — | 2002-09-24 | — | — | JP | claimed |
| EP-1133288-A1 | THE USE OF ARYL-SUBSTITUTED CYCLOBUTYLALKYLAMINES FOR TREATING URINARY INCONTINENCE | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-09-19 | — | — | EP | claimed |
| US-6127424-A | N-METHYL-1-(1-(4-CHLOROPHENYL)CYCLOBUTYL)-3-METHYLBUTYLAMINE OR A PHARMACEUTICALLY SUITABLE SALT AS AN EXAMPLE; BIOAVAILABILITY; SIDE EFFECT REDUCTION | KNOLL AKTIENGESESLLSCHAFT (DE) | 2000-10-03 | — | — | US | claimed |
| WO-2000032182-A1 | THE USE OF ARYL-SUBSTITUTED CYCLOBUTYLALKYLAMINES FOR TREATING URINARY INCONTINENCE | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-06-08 | — | — | WO | claimed |
| US-6046242-A | ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF CHLOROBENZENE SUBSTITUTED CYCLOBUTYLALKYLAMINE COMPOUND TO TREAT URINARY INCONTINENCE | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-04 | — | — | US | claimed |
| US-8911751-B2 | Compositions for nasal delivery | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2014-12-16 | — | — | US | disclosed |
| US-8114844-B2 | Linear and cyclic melanocortin receptor-specific peptidomimetics | PALATIN TECHNOLOGIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| EP-1933809-B1 | COMPOSITIONS FOR NASAL DELIVERY | YISSUM RES DEV CO (IL) | 2012-02-08 | — | — | EP | disclosed |
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7964601-B2 | Agonist or antgonist and binders and inversion of agonist | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7834017-B2 | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents | PALATIN TECHNOLOGIES, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7732451-B2 | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| WO-2000032182-A1 | THE USE OF ARYL-SUBSTITUTED CYCLOBUTYLALKYLAMINES FOR TREATING URINARY INCONTINENCE | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-06-08 | — | — | WO | disclosed |
| US-6046242-A | ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF CHLOROBENZENE SUBSTITUTED CYCLOBUTYLALKYLAMINE COMPOUND TO TREAT URINARY INCONTINENCE | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-04 | — | — | US | disclosed |
| US-6046242-A | ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF CHLOROBENZENE SUBSTITUTED CYCLOBUTYLALKYLAMINE COMPOUND TO TREAT URINARY INCONTINENCE | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-04 | — | — | US | disclosed |
| US-6046242-A | ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF CHLOROBENZENE SUBSTITUTED CYCLOBUTYLALKYLAMINE COMPOUND TO TREAT URINARY INCONTINENCE | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-04 | — | — | US | disclosed |
| EP-0828484-A1 | USE OF ARYL SUBSTITUTED CYCLOBUTYL ALKYL AMINES FOR THE TREATMENT OF OBESITY | Knoll AG (DE) | 1998-03-18 | — | — | EP | disclosed |
| EP-0828484-A1 | USE OF ARYL SUBSTITUTED CYCLOBUTYL ALKYL AMINES FOR THE TREATMENT OF OBESITY | Knoll AG (DE) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996038134-A1 | USE OF ARYL SUBSTITUTED CYCLOBUTYL ALKYL AMINES FOR THE TREATMENT OF OBESITY | KNOLL AG (DE) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996038134-A1 | USE OF ARYL SUBSTITUTED CYCLOBUTYL ALKYL AMINES FOR THE TREATMENT OF OBESITY | KNOLL AG (DE) | 1996-12-05 | — | — | WO | disclosed |